Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.
Korea-based Bridge Biotherapeutics closes Boston office
Bridge Biotherapeutics has closed its Boston-area discovery wing, according to sources familiar with the decision by the South Korean drug developer. The closure came in
June 25, 2024